Wondm Samuel Agegnew, Dagnew Samuel Berihun, Gubae Kale, Tesfaye Tegenu Chanie, Tamene Fasil Bayafers
Clinical Pharmacy Unit, Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Clinical Pharmacy Unit, Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Front Med (Lausanne). 2024 Jul 11;11:1415877. doi: 10.3389/fmed.2024.1415877. eCollection 2024.
Chemotherapy-induced anemia (CIA) is a hematologic complication that frequently affects patients with cancer undergoing chemotherapy. It is associated with worse treatment outcomes, higher rates of morbidity and mortality, worse quality of life, and higher healthcare costs. The incidence and predictors of CIA in Ethiopia, particularly in Northwest Ethiopian oncology centers, are poorly understood. This study was conducted at Northwest Ethiopian oncology centers to evaluate the incidence and determinants of chemotherapy-induced anemia in adult patients with cancer undergoing chemotherapy.
This 3-year hospital-based retrospective follow-up study included adult patients with cancer receiving chemotherapy between 2019 and 2021 at two oncology centers in Northwest Ethiopia. Data were collected from October to December 2021. A binary logistic regression model was used to select variables and determine the Crude Odds Ratio (COR). Variables with -value < 0.2 were entered into the multivariable logistic regression and Adjusted odds ratio (AOR) with 95% Confidence intervals (CI) for variables with -value < 0.05 were estimated to show determinants of chemotherapy-induced anemia among cancer patients who received chemotherapy.
A total of 402 patients were included in the final analysis. The overall incidence of CIA was 75.4% (95% CI 70.7, 79.8). Older age [AOR = 1.8, 95% CI (1.4-3.5); = 0.043], hematologic cancer [AOR = 3.7, 95% CI (3.2-5.7), = 0.021], obesity [AOR = 3.4, 95% CI (2.3-6.9); = 0.028], ≥6 chemotherapy cycles [AOR = 3.8, 95% CI (3.2-5.1), = 0.019], cancer metastasis to bone [AOR = 2.9, 95% CI (1.2-4.7), = 0.025] were statistically significant predictors of chemotherapy-induced anemia.
Chemotherapy-induced anemia persisted in a significant percentage of cancer patients. Chemotherapy-induced anemia developed in three-quarters of patients undergoing chemotherapy. Chemotherapy-induced anemia was significantly associated with older age, hematologic malignancy, obesity, a greater number of chemotherapy cycles, and cancer metastasis to bone. To lower the risk of morbidity related to anemia, patients with chemotherapy-induced anemia should be regularly evaluated and treated with appropriate treatment.
化疗引起的贫血(CIA)是一种血液学并发症,经常影响接受化疗的癌症患者。它与更差的治疗结果、更高的发病率和死亡率、更差的生活质量以及更高的医疗成本相关。埃塞俄比亚CIA的发病率和预测因素,尤其是在埃塞俄比亚西北部的肿瘤中心,了解甚少。本研究在埃塞俄比亚西北部的肿瘤中心进行,以评估接受化疗的成年癌症患者中化疗引起的贫血的发病率和决定因素。
这项为期3年的基于医院的回顾性随访研究纳入了2019年至2021年期间在埃塞俄比亚西北部两个肿瘤中心接受化疗的成年癌症患者。数据于2021年10月至12月收集。使用二元逻辑回归模型选择变量并确定粗比值比(COR)。将P值<0.2的变量纳入多变量逻辑回归,并估计P值<0.05的变量的调整比值比(AOR)及其95%置信区间(CI),以显示接受化疗的癌症患者中化疗引起的贫血的决定因素。
共有402名患者纳入最终分析。CIA的总体发病率为75.4%(95%CI 70.7,79.8)。年龄较大[AOR = 1.8,95%CI(1.4 - 3.5);P = 0.043]、血液系统癌症[AOR = 3.7,95%CI(3.2 - 5.7),P = 0.021]、肥胖[AOR = 3.4,95%CI(2.3 - 6.9);P = 0.028]、≥6个化疗周期[AOR = 3.8,95%CI(3.2 - 5.1),P = 0.019]、癌症转移至骨[AOR = 2.9,95%CI(1.2 - 4.7),P = 0.025]是化疗引起的贫血的统计学显著预测因素。
化疗引起的贫血在相当比例的癌症患者中持续存在。四分之三接受化疗的患者发生了化疗引起的贫血。化疗引起的贫血与年龄较大、血液系统恶性肿瘤、肥胖、化疗周期数较多以及癌症转移至骨显著相关。为降低与贫血相关的发病风险,应定期评估化疗引起的贫血患者,并给予适当治疗。